TrialNet is celebrating 20 years!

TrialNet Chair Dr. Kevan Herold celebrates 20 years of progress, looks forward to making T1D a disease of the past

In

When you take part in TrialNet type 1 diabetes (T1D) risk screening, a few drops of blood can make a big difference. In addition to learning your risk for developing T1D—often years before symptoms appear—you’re joining the TrialNet #T1Dfamily, the world’s largest clinical trial network ever assembled to change the course of T1D.

Kevan C. Herold, MD, C.N.H. Long Professor of Immunology and professor of medicine (endocrinology) at Yale School of Medicine, was recently appointed TrialNet Chair, succeeding Carla J. Greenbaum, MD, who served six years in the position.

New TrialNet research findings published today in Science Translational Medicine show that a 14-day course of the immunotherapy drug teplizumab provided an additional year of delay in onset of type 1 diabetes and improved insulin production, increasing the overall benefit to high-risk individuals reported in the original study fin

Now enrolling adults diagnosed with T1D in the past 4 years 

TrialNet is excited to announce the launch of our first Phase 1 clinical study to test a new plasmid therapy. The study will enroll 48 adults (age 18-45) diagnosed with type 1 diabetes (T1D) in the past 4 years.